Therapeutic gene silencing strategies for polyglutamine disorders. by Scholefield, J, Wood, M

Polyglutamine disease: from pathogenesis to therapy. by Watson, L, Scholefield, J, Greenberg, L, Wood, M

Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. by Scholefield, J, Greenberg, L, Weinberg, MS, Arbuthnot, P, Abdelgany, A, Wood, M

Spinocerebellar ataxia type 7 in South Africa: epidemiology, pathogenesis and therapy by Watson, L, Smith, D, Scholefield, J, Ballo, R, Kidson, S, Greenberg, L, Wood, M

Molecular and electrophysiological features of spinocerebellar ataxia type seven in induced pluripotent stem cells. by Burman, RJ, Watson, LM, Smith, DC, Raimondo, JV, Ballo, R, Scholefield, J, Cowley, SA, Wood, MJA, Kidson, SH, Greenberg, LJ

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. by Bramhall, SR, Hallissey, M, Whiting, J, Scholefield, J, Tierney, G, Stuart, R, Hawkins, R, McCulloch, P, Maughan, T, Brown, P, Baillet, M, Fielding, J

Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial. by Mant, D, Perera, R, Gray, A, Rose, P, Fuller, A, Corkhill, A, George, S, Little, L, Regan, S, Mellor, J, Pugh, SA, Northover, J, Weaver, A, Barsoum, G, Tan, LT, Mortensen, N, Scholefield, J, Wasan, H, Ferry, D, Primrose, J